Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/THRAP3_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/THRAP3_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/THRAP3_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/THRAP3_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/THRAP3_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/THRAP3_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/THRAP3_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/THRAP3_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/THRAP3_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000037513 | Lung | AIS | RNA splicing, via transesterification reactions | 49/1849 | 324/18723 | 1.69e-03 | 1.93e-02 | 49 |
GO:003312013 | Lung | AIS | positive regulation of RNA splicing | 10/1849 | 37/18723 | 2.48e-03 | 2.55e-02 | 10 |
GO:190331213 | Lung | AIS | negative regulation of mRNA metabolic process | 18/1849 | 92/18723 | 3.54e-03 | 3.34e-02 | 18 |
GO:004348433 | Lung | MIAC | regulation of RNA splicing | 32/967 | 148/18723 | 3.60e-12 | 9.23e-09 | 32 |
GO:190331132 | Lung | MIAC | regulation of mRNA metabolic process | 45/967 | 288/18723 | 2.75e-11 | 4.70e-08 | 45 |
GO:004802432 | Lung | MIAC | regulation of mRNA splicing, via spliceosome | 24/967 | 101/18723 | 2.28e-10 | 2.92e-07 | 24 |
GO:005068432 | Lung | MIAC | regulation of mRNA processing | 26/967 | 137/18723 | 7.19e-09 | 4.94e-06 | 26 |
GO:000038122 | Lung | MIAC | regulation of alternative mRNA splicing, via spliceosome | 14/967 | 60/18723 | 1.64e-06 | 2.10e-04 | 14 |
GO:004348831 | Lung | MIAC | regulation of mRNA stability | 23/967 | 158/18723 | 6.62e-06 | 6.29e-04 | 23 |
GO:004348731 | Lung | MIAC | regulation of RNA stability | 24/967 | 170/18723 | 7.20e-06 | 6.53e-04 | 24 |
GO:006101331 | Lung | MIAC | regulation of mRNA catabolic process | 23/967 | 166/18723 | 1.52e-05 | 1.07e-03 | 23 |
GO:000838023 | Lung | MIAC | RNA splicing | 44/967 | 434/18723 | 1.56e-05 | 1.07e-03 | 44 |
GO:000640231 | Lung | MIAC | mRNA catabolic process | 28/967 | 232/18723 | 2.65e-05 | 1.66e-03 | 28 |
GO:000038022 | Lung | MIAC | alternative mRNA splicing, via spliceosome | 14/967 | 77/18723 | 3.50e-05 | 1.97e-03 | 14 |
GO:190331223 | Lung | MIAC | negative regulation of mRNA metabolic process | 15/967 | 92/18723 | 6.98e-05 | 3.38e-03 | 15 |
GO:190331322 | Lung | MIAC | positive regulation of mRNA metabolic process | 17/967 | 118/18723 | 1.17e-04 | 4.92e-03 | 17 |
GO:000037723 | Lung | MIAC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 33/967 | 320/18723 | 1.27e-04 | 5.13e-03 | 33 |
GO:000039823 | Lung | MIAC | mRNA splicing, via spliceosome | 33/967 | 320/18723 | 1.27e-04 | 5.13e-03 | 33 |
GO:000037523 | Lung | MIAC | RNA splicing, via transesterification reactions | 33/967 | 324/18723 | 1.61e-04 | 6.19e-03 | 33 |
GO:003133033 | Lung | MIAC | negative regulation of cellular catabolic process | 28/967 | 262/18723 | 2.23e-04 | 7.67e-03 | 28 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
THRAP3 | SNV | Missense_Mutation | novel | c.953N>A | p.Gly318Asp | p.G318D | Q9Y2W1 | protein_coding | tolerated(0.22) | benign(0.215) | TCGA-A7-A6VX-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | CR |
THRAP3 | SNV | Missense_Mutation | | c.2428N>A | p.Asp810Asn | p.D810N | Q9Y2W1 | protein_coding | tolerated(0.69) | possibly_damaging(0.873) | TCGA-A8-A07B-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
THRAP3 | SNV | Missense_Mutation | | c.869N>A | p.Gly290Asp | p.G290D | Q9Y2W1 | protein_coding | tolerated(0.07) | possibly_damaging(0.726) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
THRAP3 | SNV | Missense_Mutation | | c.880N>G | p.Gln294Glu | p.Q294E | Q9Y2W1 | protein_coding | tolerated(0.12) | possibly_damaging(0.79) | TCGA-BH-A1EV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
THRAP3 | SNV | Missense_Mutation | | c.144N>C | p.Arg48Ser | p.R48S | Q9Y2W1 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.994) | TCGA-BH-A1FU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
THRAP3 | SNV | Missense_Mutation | rs749716914 | c.2080G>A | p.Asp694Asn | p.D694N | Q9Y2W1 | protein_coding | deleterious(0.02) | possibly_damaging(0.709) | TCGA-C8-A131-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
THRAP3 | SNV | Missense_Mutation | | c.2081A>T | p.Asp694Val | p.D694V | Q9Y2W1 | protein_coding | deleterious(0) | possibly_damaging(0.848) | TCGA-C8-A131-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
THRAP3 | SNV | Missense_Mutation | | c.302N>C | p.Arg101Pro | p.R101P | Q9Y2W1 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
THRAP3 | SNV | Missense_Mutation | | c.1403N>T | p.Ser468Leu | p.S468L | Q9Y2W1 | protein_coding | tolerated(0.67) | benign(0.15) | TCGA-E2-A9RU-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | arimidex | SD |
THRAP3 | SNV | Missense_Mutation | | c.320A>C | p.Tyr107Ser | p.Y107S | Q9Y2W1 | protein_coding | deleterious(0.01) | probably_damaging(0.918) | TCGA-E9-A1N8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |